Drug Profile
Insulin biosimilar - Wockhardt
Alternative Names: Recombinant (r-DNA) regular short acting human insulin - Wockhardt; Wosulin-RLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-III for Type 1 diabetes mellitus in USA (SC)
- 29 Aug 2016 Wockhardt plans a phase I trial for Type-1 diabetes mellitus (In volunteers) in India (CTRI2016-02-006645)
- 29 Aug 2016 Wockhardt terminates phase I bioequivalence trial in Type-1 diabetes mellitus in India (CTRI2015-05-005801) before August 2016